Friday, June 19, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “eli lilly” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 169
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 169 pipeline programs matching "eli lilly" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

169 results for “eli lilly” Back to intelligence hub

Search results

Page 7 of 8
  1. LOXO-LNC-24001

    Eli Lilly Co.

    Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors

    phase 1 other active

    1 trial
  2. LOXO-PIK-21001

    Eli Lilly Co.

    Advanced Breast Cancer and Other Solid Tumors

    phase 1 other active

    1 trial
  3. LY3039478

    Eli Lilly and Company

    Advanced Solid Tumor

    phase 1 small molecule completed

    1 trial
  4. LY3053102

    Eli Lilly and Company

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial
  5. LY3209590 (SC)

    Eli Lilly and Company

    Healthy

    phase 1 small molecule completed

    1 trial
  6. LY3484356

    Eli Lilly and Company

    Breast Neoplasms

    phase 1 small molecule active

    1 trial
  7. LY3493269

    Eli Lilly and Company

    Healthy

    phase 1 small molecule terminated

    1 trial
  8. LY3493269 - SC

    Eli Lilly and Company

    Healthy

    phase 1 small molecule completed

    1 trial
  9. LY3532226

    Eli Lilly and Company

    Obesity

    phase 1 small molecule completed

    1 trial
  10. LY3537021

    Eli Lilly and Company

    Healthy

    phase 1 small molecule completed

    1 trial
  11. LY3819469

    Eli Lilly and Company

    Healthy

    phase 1 small molecule completed

    1 trial
  12. LY4006896

    Eli Lilly and Company

    Parkinson Disease

    phase 1 small molecule active

    1 trial
  13. Olaratumab

    Eli Lilly and Company

    Malignancy

    phase 1 mab completed

    1 trial
  14. Olomorasib

    Eli Lilly and Company

    Healthy

    phase 1 small molecule completed

    1 trial
  15. Tabalumab

    Eli Lilly and Company

    Multiple Myeloma

    phase 1 mab completed

    1 trial
  16. Tirzepatide

    Eli Lilly and Company

    Healthy

    phase 1 small molecule completed

    1 trial
  17. Abemaciclib

    Eli Lilly and Company

    Breast Neoplasms

    approved small molecule completed

    1 trial
  18. Abemaciclib

    Eli Lilly and Company

    Metastatic Breast Cancer

    approved small molecule terminated

    1 trial
  19. I4V-MC-JAJA

    Eli Lilly Co.

    Rheumatoid Arthritis

    approved small molecule active

    1 trial
  20. I6T-MC-AMCA

    Eli Lilly Co.

    severely active ulcerative colitis (US) and CD (Crohn’s disease)

    approved small molecule active

    1 trial
  21. Insulin Glargine

    Eli Lilly and Company

    Diabetes Mellitus, Type 2

    approved small molecule completed

    1 trial
  22. Insulin lispro low mixture

    Eli Lilly and Company

    Type 2 Diabetes Mellitus

    approved small molecule completed

    1 trial
  23. SELPERCATINIB, SELPERCATINIB

    Eli Lilly Co.

    Non Small Cell Lung Cancer; Medullary Thyroid Cancer; Colon Cancer; Breast Cancer; Pancreatic Cancer; Papillary Thyroid Cancer; Other Solid Tumors With Evidence of Activating RET Alteration;

    approved small molecule active

    1 trial
  24. premeal insulin lispro mixtures

    Eli Lilly and Company

    Diabetes Mellitus, Type 2

    approved small molecule completed

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.